Intellectus Partners, LLC Glycomimetics Inc Transaction History

Intellectus Partners, LLC

$383 Million
Q3 2024

A detailed history of Intellectus Partners, LLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Intellectus Partners, LLC holds 45,965 shares of GLYC stock, worth $10,571. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,965

Previous 45,965 -0.0%

Holding current value

$10,571

Previous $12,000 41.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$0.24 - $3.04 $1,141 - $14,455	-4,755 Reduced 9.38%	45,965 $12,000
Q4 2023 Feb 05, 2024	SELL	$1.13 - $2.54 $12,718 - $28,587	-11,255 Reduced 18.16%	50,720 $119,000
Q3 2023 Oct 25, 2023	SELL	$1.29 - $1.73 $14,835 - $19,895	-11,500 Reduced 15.65%	61,975 $92,000
Q2 2023 Jul 31, 2023	SELL	$1.21 - $2.08 $9,988 - $17,170	-8,255 Reduced 10.1%	73,475 $127,000
Q4 2022 Feb 02, 2023	SELL	$0.57 - $3.03 $22,098 - $117,473	-38,770 Reduced 32.17%	81,730 $247,000
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.9 $17,875 - $29,250	32,500 Added 36.93%	120,500 $66,000
Q2 2022 Aug 12, 2022	SELL	$0.54 - $1.15 $1,350 - $2,875	-2,500 Reduced 2.76%	88,000 $53,000
Q1 2022 May 16, 2022	BUY	$1.0 - $1.58 $10,000 - $15,800	10,000 Added 12.42%	90,500 $103,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $61,200 - $90,950	-42,500 Reduced 34.55%	80,500 $115,000
Q2 2021 Aug 13, 2021	BUY	$2.16 - $3.18 $90,720 - $133,560	42,000 Added 51.85%	123,000 $285,000
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $205,190 - $299,620	71,000 Added 710.0%	81,000 $244,000
Q4 2020 Feb 18, 2021	BUY	$2.69 - $4.24 $26,900 - $42,400	10,000 New	10,000 $38,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $12.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.

Account

Intellectus Partners, LLC Glycomimetics Inc Transaction History